Overview
Melanotan I (MT1), clinically known as afamelanotide, is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring neuropeptide derived from proopiomelanocortin (POMC). Developed initially at the University of Arizona, MT1 was engineered to be a more potent and metabolically stable version of α-MSH, with a half-life of approximately 1.5 hours compared to the native hormone's minutes-long duration. MT1 is the only melanocortin receptor agonist to have received regulatory approval — it is approved in the European Union under the brand name Scenesse® for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP), a rare genetic disorder causing extreme light sensitivity. This clinical validation distinguishes MT1 from most research peptides and provides a robust human safety and efficacy dataset.
Mechanism of Action
MT1 functions as a potent agonist of the melanocortin-1 receptor (MC1R), a G-protein coupled receptor expressed predominantly on melanocytes in the skin. Upon binding to MC1R, MT1 activates the Gαs protein, stimulating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP) levels. Elevated cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB (cAMP response element-binding protein). Phosphorylated CREB activates the microphthalmia-associated transcription factor (MITF), the master regulator of melanocyte biology. MITF drives expression of tyrosinase, tyrosinase-related protein-1 (TRP-1), and TRP-2 — the key enzymes of the melanogenesis pathway —
Research Evidence
- EU-approved (Scenesse®) for prevention of phototoxicity in erythropoietic protoporphyria
- ~100-fold greater MC1R binding affinity than native α-MSH due to D-Phe substitution
- Increases eumelanin production without requiring UV exposure
- Demonstrated significant reduction in phototoxic reactions in EPP clinical trials
- Anti-inflammatory activity via MC1R-mediated suppression of NF-κB signaling
Bottom line: MT1 stands apart from most research peptides because it has genuine clinical validation behind it. The EU-approved formulation is a subcutaneous implant; Purgo Labs supplies the lyophilized powder format strictly for laboratory research use. The clinical data provides a strong mechanistic foundation for researchers studying melanocortin biology.
Research Protocols & Dosage
Evidence-based research protocols, administration routes, and dosage considerations for MT1 are detailed in the full compound profile. See also: Dosage guide for MT1.
Sourcing & Quality
MT1 is available from Purgo Labs with third-party COA verification and research-grade purity standards. View MT1 at Purgo Labs.